Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group.
The EORTC Melanoma Cooperative Group conducted a phase II trial (study number 18891) to study the effect of Toremifene in 45 patients with advanced, metastatic melanoma. Male and female patients, median age 61 (range 23-88) years received a mean total dose of 11 g (4.3-62.6) orally for at least 6 weeks. No objective remissions were seen. Four patients (3 women and 1 man; 9%) experienced 3-6 months' disease stabilization. The toxicity of the drug, given at a dose of 240 mg daily, was negligible. Because of the minimal side-effects, Toremifene may be recommended for patients who have only a small number of slowly growing metastases, in particular to soft tissue and lung.
Kleeberg
U R
UR
Hämatologisch-Onkologische Praxis Altona, Hamburg, Germany.
Engel
E
E
Bröcker
E B
EB
Avril
F
F
Israels
P
P
Weiss
J
J
Kangas
L
L
van Glabbeke
M
M
Lentz
M A
MA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008593:Menopause; D008875:Middle Aged; D012737:Sex Factors; D012878:Skin Neoplasms / Q000556:secondary; D012983:Soft Tissue Neoplasms / Q000556:secondary; D017312:Toremifene / Q000009:adverse effects / Q000627:therapeutic use*
D017312:Toremifene